Brentuximab vedotin is approved in the United States for the treatment of systemic anaplastic large cell lymphoma (ALCL) and Hodgkin lymphoma. In this study, researchers are evaluating its effectiveness for treating newly diagnosed peripheral T-cell lymphoma (PTCL) when it is given in combination with three standard chemotherapy drugs.
The most common initial treatment for PTCL is CHOP, a combination of the drugs cyclophosphamide, hydroxydaunorubicin, vincristine (Oncovin), and prednisone. Patients in this study will be randomly assigned to receive CHOP, or brentuximab vedotin plus cyclophosphamide, hydroxydaunorubicin, and prednisone (CHP).
Brentuximab has two parts: one (an antibody) that attaches to a protein on the surface of cancer cells called CD30, and another (an anticancer drug called monomethyl auristatin E) that kills the cancer. Patients in this study must have PTCL that contains the CD30 protein.